Lubner David Charles 4

What Happened

• David Charles Lubner, a director of Dyne Therapeutics (DYN), was granted an equity award on June 5, 2026. The Form 4 reports a derivative award for 35,152 shares at $0.00 (transaction code A), indicating an option/grant rather than a purchase or sale. The filing was submitted on June 9, 2026.

Key Details

• Transaction date: 2026-06-05; Filing date: 2026-06-09 (filed within the usual two-business-day Form 4 deadline for a June 5 trade).
• Security: derivative award (option/grant) covering 35,152 shares; reported price $0.00 in the filing.
• Shares owned after transaction: not specified in the provided excerpt.
• Footnote: The option vests in full on the earlier of (i) June 5, 2027 or (ii) the issuer’s 2027 Annual Meeting of Stockholders, subject to continued service.
• Transaction type/code: A = Award/Grant (derivative).

Context

• This was an equity award (option grant). A $0.00 reported acquisition value means the filing records the grant itself; any future economic value depends on vesting and future stock price and any exercise terms (exercise price not provided here). Awards to directors are common compensation and do not, by themselves, indicate buying or selling intent.